AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s stock price traded down 4.4% during mid-day trading on Thursday . The company traded as low as $3.45 and last traded at $3.47. Approximately 82,984 shares traded hands during mid-day trading, an increase of 429% from the average session volume of 15,685 shares. The stock had previously closed at $3.63.
AlloVir Stock Down 4.4%
The company’s 50-day simple moving average is $4.10 and its 200 day simple moving average is $5.45. The stock has a market capitalization of $17.50 million, a price-to-earnings ratio of -0.17 and a beta of 0.63.
AlloVir Company Profile
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Further Reading
- Five stocks we like better than AlloVir
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
